Table 2.
Most commonly identified toxicities for pelareorep in combination with gemcitabine. (>10% of patients).
| Toxicity * | Total % | Grade 3% | Grade 4% |
|---|---|---|---|
| Hematologic | |||
| Anemia | 35 | 24 | 3 |
| Neutropenia | 32 | 15 | 12 |
| Thrombocytopenia | 15 | 6 | 0 |
| Non-Hematologic | |||
| Diarrhoea | 24 | 0 | 0 |
| Nausea | 29 | 0 | 0 |
| Vomiting | 24 | 0 | 0 |
| Fatigue | 71 | 9 | 0 |
| Chills/Flu-like symptoms | 51 | 0 | 0 |
| Edema | 33 | 0 | 0 |
| Fever | 56 | 0 | 0 |
| AST increased | 12 | 6 | 0 |
| Anorexia/Weight loss | 33 | 0 | 0 |
| Dyspnea | 50 | 6 | 0 |
* Toxicities are reported as per the National Cancer Institute (NCI) common toxicity criteria 3.0; numbers are % of patients. AST: aspartate aminotransferase.